Participants
This study was approved by the Fred Hutchinson Cancer Research Center
(FHCRC) Institutional Review Board. FHCRC maintains continuous follow-up
of HCT survivors who consent to long-term follow-up via an annual
patient-reported health survey, with the earliest transplant performed
in 1971.17,18 Patients underwent HCT for both
malignant and non-malignant conditions, including immunodeficiencies and
benign hematologic disorders. The following HCT survivors were eligible
for this study: alive ≥1 year after HCT at FHCRC, age <21
years at time of transplant, current age ≥18 years at the time of
survey, and available current mailing address. Baseline demographic
characteristics (including age, sex, race and ethnicity, underlying
diagnosis) and HCT details (including conditioning regimen, donor type,
chronic graft versus host disease (cGVHD) status) were retrieved from
the FHCRC research database. Additionally, pre-HCT cranial irradiation
exposure was abstracted from the medical record.